The objective of this study was to determine whether constipation-predominant irritable bowel syndrome (IBS-C) is associated with changes in intestinal barrier and secretory function.
INTRODUCTION
Irritable bowel syndrome (IBS) is a common and chronic gastrointestinal disorder that results in signifi cant morbidity and health-care utilization. Although several peripheral and central mechanisms have been shown to play a role, the pathophysiology of IBS remains to be clarifi ed ( 1 ) . More recently, an increase in intestinal permeability has been shown to be present in a subset of patients with diarrhea-predominant IBS and was found to correlate with visceral sensitivity and symptom severity ( 2 ) .
Paracellular permeability is primarily regulated by the tight junctions (TJs) composed of integral membrane (claudins, occludin) and structural binding proteins (zonula occludens (ZO)).
Most of the existing literature reporting increased intestinal permeability in IBS focuses on diarrhea-predominant IBS (IBS-D) or postinfectious IBS that is usually IBS-D or mixed IBS.
Little is known about intestinal permeability alterations in IBS-C. Two studies reported increased fl ux of fl uorescein-5.6 sulfonic acid (478 Dalton) across colonic biopsies of IBS-C patients (number of subjects: 3 and 10) as compared with healthy subjects ( 3, 4 ) . Another study showed that colonic biopsy supernatant of all IBS subtypes reduced transepithelial resistance and increased fl ux of fl uorescein isothiocyanate (FITC)-dextran (4 kDa) across Caco-2 monolayers ( 3 ). Colonic epithelial protein expression of occludin was found to be decreased in small studies of patients with IBS-C ( 5, 6 ) . Another study showed unchanged claudin-1 protein expression in IBS-C as compared with healthy individuals ( 7 ) . Th e in vivo measurements of intestinal permeability using urinary excretion of orally ingested, poorly absorbable saccharides have also shown variable results in IBS-C. One study has shown increased permeability using polyethylene glycol 3350/400 (ref. 8 ) , another using polyethylene glycol 400/1500/4000 showed no diff erence ( 9 ) , and one using 51 Cr-EDTA showed decreased permeability ( 10 ) . Variability in timing of urine collection and dietary contamination oft en limits interpretation from these in vivo assays.
In a validation study using lactulose and mannitol, cumulative collections between 0 and 2 h and between 8 and 24 h were found to be most refl ective of small bowel and colonic permeability, respectively ( 11 ) . In addition, we have noted that up to 30% of participants can have a high baseline (before administration of the test dose) presence of mannitol that can interfere with the test performance. Our studies showed that 13 C mannitol has better performance characteristics and can be used as a novel saccharide for measurement of intestinal permeability ( 12 ) . Additionally, mucosal secretory function has not been studied in IBS-C.
Th e overall objective of this study was to use a comprehensive and comparative methodological approach to determine changes in mucosal barrier and secretory functions in females patients with IBS-C compared with healthy volunteers. Specifi c goals were to compare in vivo permeability, in vivo mucosal impedance, ex vivo duodenal and colonic mucosal barrier function, mucosal bacterial translocation, and circulating endotoxemia in females with IBS-C in comparison with healthy volunteers. In addition, we investigated baseline and acetylcholine (ACh)-evoked mucosal secretory properties and colonic TJ gene expression in IBS-C in comparison with healthy volunteers.
METHODS

Subjects
Th e study population consisted of 19 Rome III IBS-C patients and 18 healthy volunteers (without a history of IBS or any other gastrointestinal disorder). All participants were females and the controls were age-matched to IBS-C cases. Neither population had history of abdominal surgery (except appendectomy or cholecystectomy), infl ammatory bowel disease, microscopic colitis, or celiac disease nor were they pregnant at the time of the study. Additional exclusion criteria included use of tobacco (within 6 months of the study), nonsteroidal anti-infl ammatory drugs, systemic antibiotics (within 1 week of the study), or oral corticosteroids (within 6 weeks of the study). In addition, any prescription, over the counter, or herbal medications that can aff ect gastrointestinal transit were prohibited 7 days before study start (e.g., osmotic laxatives, antiemetics, prokinetics, anticholinergics, narcotics, peppermint oil, or antidepressants with known eff ects on intestinal transit). Participants were also excluded if they scored higher than 8 for anxiety or depression on a Hospital Anxiety and Depression Scale (HADS). None of the participants were on a type 2 chloride channel activator, guanylate cyclase C agonist, or 5-HT4 agonist at the time of the study. Th e IBS-C participants completed IBS-symptom severity scale ( 13 ) , IBS-quality of life ( 14 ) , and somatic symptom checklist. Th e study was approved by the institutional review board at Mayo Clinic and all subjects provided written informed consent before participation. Th e study was listed on ClinicalTrials.gov (NCT02246647).
In vivo intestinal permeability
Saccharide excretion assay . We used a recently developed assay for in vivo measurement of intestinal permeability using 13 C mannitol and lactulose ( 12 ) . Volunteers were instructed to not consume artifi cial sweeteners such as Splenda (sucralose), Nutrasweet (aspartame), lactulose, or mannitol for 2 days before permeability testing. Th ey were orally administered 1,000 mg lactulose, 100 mg 12 C (regular) mannitol, and 100 mg 13 C mannitol dissolved in 250 ml of water. Urine samples were collected at baseline (before test saccharide administration) and 0-2, 2-8, and 8-24 h aft er saccharide administration. High-performance liquid chromatography-tandem mass spectrometry was used to measure saccharide concentrations as previously described ( 12 ) . Cumulative concentrations were calculated using the overall urine volume excreted in the individual intervals. Concentrations of 13 C were adjusted for the percentage of 13 C in 12 C mannitol (4.98% of 12 C mannitol excreted was subtracted from 13 C mannitol values; determined by analyzing replicate samples of control urine). Cumulative lactulose or 13 C mannitol concentrations between 0 and 2 h and between 8 and 24 h were used for determination of small bowel and colonic permeability, respectively. Respective lactulose to 13 C mannitol excretion ratios, as a measure of dose of saccharide administered, were calculated for the 0-2 h and 8-24 h intervals.
Duodenal impedance . All participants fasted for 8 h and underwent sedated esophagogastroduodenoscopy. Duodenal impedance measurements were performed using a recently designed endoscopically passed catheter that measures electrical impedance of the duodenal epithelium by mucosal contact under direct visualization ( 15 ) . A 2 mm diameter catheter was used with two 360° circumferential sensors placed at a separation of 2 mm with the end of the distal ring being 1 mm away from the catheter tip. Th e electrodes were connected to an impedance voltage transducer via thin wires that ran the length of the catheter traversing through the working channel of the upper endoscope. Th e voltage generated by the transducer was limited to produce 10 μ A current
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Barrier and Secretory Function in Females With IBS-C at a frequency of 2 kHz. Impedance measurements were expressed in Ω as the ratio of voltage to the current. Data were acquired with a stationary impedance data acquisition system (InSight; Sandhill Scientifi c) and were analyzed using BioView analysis soft ware (Sandhill Scientifi c, Denver, CO). Impedance was measured every 90° in duodenal circumference with a decompressed lumen aft er suctioning of all fl uid from the lumen. Th e catheter was embedded in the mucosa parallel to the two sensors and measurements were taken from a steady baseline for >10 s. Average of the four values was calculated for each patient.
Endotoxemia activity assay (EAA)
Fasting, EDTA anticoagulated, whole blood was collected from all participants. Samples were analyzed using an EAA kit (Spectral Diagnostic, Toronto, ON, Canada) that utilizes a monoclonal IgM antibody specifi c for Gram-negative bacterial lipopolysaccharide. Samples were tested in duplicate within 1 h of collection using a Berthold SmartLine luminometer (Bad Wildbad, Germany) (photon-counting). Th e endotoxin activity level was calculated as follows: chemiluminescence (test sample−negative control)/ chemiluminescence (positive−negative control). Average values for each participant were expressed as absolute units.
Ex vivo mucosal barrier function
Biopsy collection . Ten duodenal biopsies were obtained from the second portion of the duodenum. At the same setting, all participants underwent a fl exible sigmoidoscopy and 10 biopsies were obtained from the sigmoid colon ∼ 30 cm from the anal verge. All endoscopic procedures were done by a single endoscopist (M.G.) and biopsies were collected using a large-capacity (2.8 mm) biopsy forceps (no pin). Th ree biopsies from each site were placed in RNAlater stabilization solution (Life Technologies, Carlsbad, CA) and fl ash frozen in liquid nitrogen. Two were placed in fi xatives (formalin, 4% paraformaldehyde). Th e rest of the biopsies were placed in Krebs solution, on ice, for Ussing chamber studies. Biopsies were immediately transported from the Clinical Research and Trials Unit to the laboratory.
Ussing chamber studies . Ussing chamber studies were performed to measure duodenal and colonic mucosal barrier function, bacterial translocation, and secretory responses. Four biopsies from each site were mounted in 4 ml Ussing chambers (Physiologic Instruments, San Diego, CA) exposing 0.031 cm 2 area, within 45 min of collection. Chambers were fi lled with Krebs with 10 mM mannitol (mucosal side) and Krebs with 10 mM glucose (submucosal side). Further details on drugs and solutions are provided in Supplementary Methods online. Baseline trans mucosal resistance (TMR) and short circuit current (Isc) of each tissue was measured using a pair of Ag/AgCl electrodes with agar-salt bridges and a pair of current-giving platinum electrodes to maintain voltage clamp conditions. Average TMR and Isc across 3-4 biopsies/subject were calculated. Secretory responses to basolateral ACh (0.01-300 μ M) was measured as the change in Isc (Δ Isc) in 1-2 biopsies/site for each subject. A positive Δ Isc indicated an anion fl ux into the lumen or a cation fl ux from luminal to serosal side. Biopsies with baseline TMR <10 Ω cm 2 , Isc drift of >100 μ A cm -2 over the experimental course, or high fl ux within 30 min of mounting were excluded from the analysis.
Paracellular fl ux across biopsies was measured using 4 kDa FITC-dextran administered on the mucosal side (1 mg/ml chamber concentration). Transcellular transport was studied using translocation of the fl uorescently labeled Escherichia coli K-12 Bio-Particles (10 7 colony-forming unit (CFUs)/ml mucosal chamber concentration). Sampling was done from the submucosal side every 30 min for a total of 3 h and cumulative fl uorescence was measured using a Synergy Multi-Mode Microplate Reader (BioTek, VT) and converted to concentration using standard curves. Cumulative fl ux at the end of 3 h and rate of fl ux was calculated for FITC-dextran and E. coli K-12 Bio-Particles. At the end of the experiment, tissue was treated with 10 μ M forskolin (activates adenylyl cyclase and increases intra cellular cyclic adenosine monophosphate) on apical side to check for tissue responsiveness.
Mucosal cellular changes
A representative duodenal and colonic biopsy from each participant was stained with hematoxylin and eosin and examined by a pathologist in a blinded manner (T.C.S.) to count eosinophils/ high-power fi eld (HPF). Immunostaining was done for mast cells using tryptase (1° rabbit anti-human (polyclonal), Santa Cruz, 1:800 dilution (Santa Cruz, CA, USA); 2° donkey anti-rabbit CY3, Millipore, 1:800 dilution (Darmstadt, Germany)) and for CD3 + cells (Mouse anti-human CD3 (monoclonal), Bio-Rad, 1:4,800 dilution (Hercules, CA, USA); 2° Donkey anti-mouse CY3, Millipore, 1:800 dilution) on 1-2 biopsies from each site (duodenum and sigmoid colon) on all participants. Th ese were graded by two independent blinded reviewers (S.E. and M.G.) as normal (0-25% increase or decrease from controls) or increased (>25% over normal).
TJ gene expression
RNA was extracted from freshly frozen colonic tissue using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) from all IBS-C patients and 10 healthy volunteers. Synthesis of complementary DNA (cDNA) from RNA was performed with an RT 2 First-Strand cDNA Kit (Qiagen). PCR was performed using an RT 2 Profi ler PCR Array for 84 human TJ genes (Qiagen). Gene expression was normalized by arithmetic mean to the control gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). As the array tested for 84 genes, statistical signifi cance level was corrected for multiple comparisons using Bonferroni correction and a P value of <0.0006 was considered signifi cant. All samples tested had a RNA integrity value of >8.
Statistical analysis
Means and s.e.m. are reported for continuous variables, whereas frequencies and percentages are reported for categorical variables. Two-sided Mann-Whitney U -test assuming non-Gaussian distribution was used to compare variables between the two groups. were done using the GraphPad Prism 7 (GraphPad Soft ware, San Diego, CA, USA). A P value of <0.05 was considered statistically signifi cant unless otherwise specifi ed. Th e sample size calculations were based on in vivo permeability parameters as primary end point. Based upon pooled data from IBS patients and healthy volunteers, 18 subjects/group allow 17% eff ect size detection for 0-2 h cumulative excretion of mannitol, 19% eff ect size detection for 8-24 h cumulative excretion of mannitol, and 30% for 8-24 h cumulative excretion of lactulose. Eff ect size is the diff erence between two groups as a percentage of the listed mean value, based on a two-sample t -test using a two-sided α -level of 0.05 and all estimates were based on 80% power. Table 1 shows demographic characteristics of study participants. All subjects were white. Anxiety and depression scores were low and comparable between the two groups. Th e mean (s.e.m.) IBS-symptom severity scale was 206 (18) on a 0-500 scale (with 500 being most severe symptoms, 175-300 categorized as moderate severity). Th e IBS-C cohort also scored low to moderate for quality-of-life impairment (mean IBS-quality of life 32, 0-100 scale) and somatization (mean somatic symptom checklist score 0.6, 0-4 scale).
RESULTS
Participant characteristics
In vivo permeability
Baseline lactulose was undetectable in both IBS-C and healthy. Cumulative baseline excretions for 13 C mannitol were signifi cantly lower than 12 C mannitol in both healthy ( 13 C mannitol: 0.06 (0.03) mg vs. Of note, there were 5 participants in IBS-C and 6 participants in the control group with a baseline urinary quantity of >5 mg of 12 C mannitol. Similar observations were made in our previously published study ( 12 ) . Hence, we used 13 C mannitol excretions as our primary measurement.
Cumulative excretion of probe molecules 0-2 h aft er ingestion . Th e cumulative 0-2 h excretion of lactulose (IBS-C: 1.17 (0.18) mg vs. healthy: 0.95 (0.07) mg, P =0.53), 13 C mannitol (IBS-C: 12.12 (0.97) mg vs. healthy: 13.20 (0.79) mg, P =0.39), and lactulose/ 13 C mannitol excretion ratio (IBS-C: 0.01 (0.001) vs. healthy: 0.007 (0.0004), P =0.25) were similar between IBS-C and healthy ( Figure 1a-c ) . Th erefore, small bowel permeability was unchanged in IBS-C.
Cumulative excretion of probe molecules 8-24 h aft er ingestion .
Th e cumulative 8-24 h excretion of lactulose (IBS-C: 0.92 (0.47) mg vs. healthy: 0.51 (0.16) mg, P =0.75), 13 C mannitol (IBS-C: 3.12 (0.70) mg vs. healthy: 3.88 (0.61) mg, P =0.08), and lactulose/ 13 C mannitol excretion ratio (IBS-C: 0.02 (0.005) vs. healthy: 0.01 (0.004), P =0.87) was similar between IBS-C and healthy ( Figure 1d-f ). Th erefore, colonic permeability in IBS-C was also unchanged.
Th e 2-8 h and the overall 0-24 h cumulative excretions were also similar between the two groups ( Supplementary Figure S2 ) . 
Ex vivo mucosal barrier function
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Secretory responses
Baseline Isc was lower in the IBS-C group in duodenum (IBS- 
Mucosal cellular changes
Th e eosinophil counts were similar in IBS-C and healthy in duodenum (IBS-C: 16.26 (1.59)/HPF vs. healthy: 18.5 (1.73)/HPF, P =0.33) and colon (IBS-C: 4.47 (1.08)/HPF vs. healthy: 3.39 (0.49)/HPF, P =0.75). Duodenal mast cells were normal in IBS-C patients. However, colonic mast cells were increased in two IBS-C patients. Duodenal and colonic CD3 + cell grading was normal in IBS-C patients.
Th ere was statistically signifi cant correlation between the 4 kDa FITC-dextran fl ux and TMR tested on the same biopsy in duodenum ( r =−0.57, P =0.0006; Figure 4a ) and colon ( r =−0.58, P =0.0012; Figure 4b ).
Duodenal impedance
Th e duodenal impedance measurement catheter ( Figure 5a ) and a representative impedance tracing is shown ( Figure 5b ) . Th e impedance values across the duodenal circumference were averaged for each subject. Th e mean impedance for IBS-C was 729.5 (64.85) Ω vs. 705.9 (42.73) Ω for healthy, P =0.71 ( Figure 5c ). Th e impedance values on the four duodenal walls ranged from 420.0 to 1,043.6 Ω in IBS-C cohort and 424.4 to 1,060.9 Ω in the healthy.
Serum endotoxemia
IBS-C patients had mean endotoxin levels of 0.36 (0.03) vs. a mean of 0.35 (0.02) in healthy, P >0.99 ( Figure 6 ). Out of 18 IBS-C patients, 3 had endotoxemia levels of >0.5 (considered high) and these 3 patients also had high colonic mucosal fl ux of FITC-dextran. 
TJ gene expression
Th e colonic mucosal expression of transmembrane proteins occludin and claudins (1-12 and 14-19) was unchanged in IBS-C. Similarly, the expression of ZO 1-3 was unchanged ( Figure 8 ) . Th e remainder of the TJ genes tested in the array were also unchanged ( Supplementary Table S1 ).
DISCUSSION
Disruption of mucosal barrier has been implicated in the pathophysiology of IBS ( 16 ) . In vivo and ex vivo measures have shown an impaired barrier function in a subset of IBS patients, mostly in IBS-D. In addition, transcriptional and protein expression of TJ proteins have been found to be altered in IBS. Finally, parameters of impaired barrier function like increased lactulose/mannitol excretion ratio ( 17 ) , increased mucosal paracellular permeability ( 4 ), and increased paracellular permeability of cellular monolayers in response to biopsy supernatants ( 3 ) have been found to correlate with the abdominal pain severity and visceral sensitivity in IBS-D. A comprehensive assessment of barrier function in IBS-C was lacking. Our results show that in this cohort of females with IBS-C who underwent detailed studies for assessment of duodenal and colonic barrier properties, in vivo and ex vivo barrier function was preserved. Th ere was no evidence of increased mucosal bacterial translocation and circulating endotoxemia in IBS-C patients. Upon assessment of secretion, IBS-C patients trended to have lower duodenal mucosal secretion as compared with healthy volunteers. In addition to helping understand pathophysiology of IBS, modulation of barrier and secretory properties is of interest for drug development in IBS-C. Th is study provides assessment of these fundamental epithelial functions in females with IBS-C and suggests that intestinal permeability and mucosal bacterial translocation are unchanged in females with IBS-C and therefore should not be targeted.
In vivo measurements of intestinal permeability are oft en done by measuring urinary excretion of molecules that are absorbed and poorly metabolized in the gut (e.g., lactulose, mannitol, rhamnose, sucralose, 51 Cr EDTA, polyethylene glycol, and so on) (18) (19) (20) . Increased lactulose/mannitol excretion ratio has been shown in postinfectious IBS following Campylobacter jejuni ( 21 ) and mixed infections ( C. jejuni and E. coli O157:H7) ( 22 ) . However, there is signifi cant interday variability in excretion of those sugars ( 23 ) and about a third of the subjects excrete signifi cant amounts of mannitol at baseline ( 12 ) . Th is could be because of inadvertent 
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C constitutes only 1% of naturally occurring carbon and is a stable (nonradioactive) isotope. We show in this study that 13 C mannitol can be separated from 12 C mannitol on contamination during the study (either from diet, medications, or other sources), baseline sugar competing with absorption, or the production of 12 C mannitol by colonic microbiota during high-performance liquid chromatography-tandem mass spectrometry and is present in extremely small concentrations in baseline urine sample, off ering a novel molecule for measurement of intestinal permeability. Our results indicate no diff erence in in vivo duodenal or colonic permeability using the 13 C mannitol excretion assay in this cohort of IBS-C females. Subsequent studies using 13 C mannitol in other IBS phenotypes (IBS-D or mixed IBS) should be able to provide a more accurate assessment of intestinal permeability than 12 C mannitol. Soluble factors have been proposed to mediate changes in mucosal barrier function and visceral sensitivity. Fecal cysteine proteases were previously found to be increased in a subset of IBS-C patients and their activity correlated with symptom severity, especially abdominal pain score. Application of IBS-C fecal supernatants on mouse colonic mucosa in vivo or cultured monolayers (T84) in vitro caused enzymatic degradation of occludin in vitro , increased permeability in vivo , and increased sensitivity to colorectal distension in vivo ( 5 ) . Two previous studies assessing colonic mucosal paracellular permeability used fl uorescein-5.6 sulfonic acid (478 Da) that is likely to have greater fl ux as compared with the FITC-dextran (4,000 Da) that we used. However, most of the dietary antigens are >600 Da, and this makes studying a larger molecule more useful for investigating barrier in disease states ( 25 ) . We also studied E. coli K-12 Bio-Particle translocation that is mediated by transcellular pathways and found no diff erences between IBS-C and health. Several factors can play a role in modulating intestinal barrier function in IBS. Psychosocial comorbidities are common in IBS and associate with symptom severity. Corticotrophinreleasing factor has been shown to increase permeability ( 26, 27 ) and TJ proteins have a rapid exchange at the junctions ( 28 ) . Th us, it is plausible that specifi c dietary or environmental triggers, such as stress, may cause intermittent disruption of barrier function mediated by the soluble factors ( 29 ) . Previous studies assessing intestinal barrier function in IBS had patients with greater levels of comorbid anxiety and depression and higher symptom severity, whereas our cohort of females with IBS-C scored fairly low on anxiety, depression, and symptom severity. In addition, environmental factors can aff ect intestinal permeability. An allergic background correlates with a more severe disease and diarrhea predominance with suggestive links with increased paracellular permeability ( 4 ). Recently, house dust mite, a common environmental trigger, was shown to increase FITC-sulfonic acid fl ux in a dose-dependent manner across human colonic mucosa, decrease ZO-1 and occludin expression, and cause damage to the TJ ultrastructure ( 30 ) .
We also studied endotoxemia levels in our cohort. Th e precise pathways that allow lipopolysaccharide entry through the gastrointestinal mucosal and defense systems into the portosystemic circulation are unknown and both trans and paracellular routes have been proposed ( 31 ) . Immune dysregulation and low-grade infl ammation have been found to be present in a subset of IBS patients. Bacterial lipopolysaccharide has been proposed to mediate and refl ect low-grade infl ammation in conditions such as obesity ( 33 ) ; however, it is not known whether IBS patients have elevated circulating endotoxins. Although, overall our IBS-C patients did not have higher endotoxemia levels than controls, 3/18 IBS-C patients had high endotoxemia levels (>0.5) that have been associated with was lower in IBS-C as compared with the healthy. Th is can result in lower luminal anionic secretion and associated luminal transport of water that can result in slower intestinal transit seen in IBS-C ( 34 ). Although ionic (Cl − ) and water secretion in colon has been studied in greater detail in animal models, mucosal secretory mechanisms in IBS-C patients have not been studied in either colon or small bowel. One study looking at transmural potential diff erence as a surrogate for intestinal secretion found elevated potential diff erence in jejunum but not duodenum in patients with IBS-C ( 35 ) . However, it is unclear whether perfusion system-based measurement of in vivo potential diff erence refl ects mucosal secretory response or correlates with transit. A recent study using surgical specimens provided detailed description of baseline secretory and barrier properties of human intestinal mucosa-submucosa preparations from a variety of disease conditions except IBS ( 36 ) . Although baseline duodenal and colonic Isc values described were lower than ours, duodenal Isc was lower than rectosigmoid colonic Isc, similar to our observations. Th is study also showed that ongoing Ach release is present in small intestine but not colon, and both Cl − and HCO 3 − secretion can play an important role in baseline Isc. Further studies should delineate ex vivo and in vivo small intestinal secretory mechanisms in IBS-C.
In summary, in this largest cohort of IBS-C females studied to date using complementary in vivo and ex vivo techniques and simultaneous assessment of small and large intestine, barrier function was not found to be altered. Th is is important considering an emerging interest for peripheral mechanisms in the pathophysiology of IBS. It is plausible that although IBS-C and IBS-D are diagnosed and conceptualized using similar mechanistic framework, the peripheral mechanisms of these two subtypes are quite diff erent. In addition, although from mechanistic and pharmacological standpoint, secretory mechanisms are better studied and targeted in colon, secretion in the small bowel probably plays an important role in pathophysiology of IBS-C and should be further studied.
